PBPanagiota Boura

Panagiota Boura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Panagiota Boura has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    T Regulatory Cells in Systemic Lupus Erythematosus: Current Knowledge and Future Prospects

    by Konstantinos Tselios, Alexandros Sarantopoulos, Ioannis Gkougkourelas, Panagiota Boura

    T Regulatory Cells in Systemic Lupus Erythematosus: Current Knowledge and Future Prospects | InTechOpen, Published on: 2017-05-31. Authors: Konstantinos Tselios, Alexandros Sarantopoulos, Ioannis Gkougkourelas, et


  • Open Access

    Celiac trunk aneurysm in a patient with Adamantiades-Behçet disease

    by Konstantinos Tselios, Kleopas-Gerasimos Chatzicharalampous, Ioannis Gkougkourelas, Alexandros Sarantopoulos, Panagiota Boura


  • Open Access

    Influenza A/H1N1 septic shock in a patient with systemic lupus erythematosus. A case report

    by Konstantinos Tselios, Ritsa Tsioka, Alexandros Sarantopoulos, Eleni Mouloudi, Panagiota Boura

    Background: Immunocompromised patients, such as systemic lupus erythematosus (SLE) sufferers have an increased risk of mortality, following influenza infection. In the recent pandemic, influenza A H1NI virus caused 18449 deaths, mainly because of adult respiratory distress syndrome or bacterial co-infections. Case Presentation: In this case report, an SLE patient with viral-induced septic shock, without overt pulmonary involvement, is discussed. The patient was administered oseltamivir and supportive treatment, including wide-spectrum antibiotics, vasopressors and steroids, according to the guidelines proposed for bacterial sepsis and septic shock. She finally survived and experienced a lupus flare soon after intensive care unit (ICU) discharge. Conclusions: To our knowledge, this is the first case to report severe septic shock from influenza A/H1N1 virus, without overt pulmonary involvement.


    • 1 July 2008
      • Vol. 12  (3) , 188-90

    Genetic polymorphism study of regulatory B cell molecules and cellular immunity function in an adult patient with Common Variable Immunodeficiency.

    by A Sarantopoulos, K Tselios, P Skendros, D Bougiouklis, I Theodorou, P Boura

    A 43 year old female patient presented for recurrent bacterial lower respiratory infections. A research for immunodeficiency status revealed total hypogammaglobulinemia, reduced IgG1, IgG2, IgG3 subclass levels, and low number of B lymphocytes (CD19+). Common Variable Immunodeficiency (CVID) 11.2 category was diagnosed according to recent criteria of primary immunodeficiencies (PID). Further immunological study consisting of genetic polymorphism of genes relating to differentiation, activation and function of B cells (ICOS, BAFF receptor BCMA and TACI) was performed, which did not reveal any related mutations. T cell parameters and Th1/Th2 cytokine network did not show any disturbances. It is postulated that probable endstage B cell differentiation defects should be investigated. The patient receives IVIGs replacement thereafter and the rate and severity of infections have significantly improved.


  • Open Access

    Chronic Brucellosis Patients Retain Low Frequency of CD4+ T-Lymphocytes Expressing CD25 and CD28 afterEscherichia coliLPS Stimulation of PHA-Cultured PBMCs

    by Panagiotis Skendros, Alexandros Sarantopoulos, Konstantinos Tselios, Panagiota Boura

    Chronic brucellosis patients display a defective Th1 response to PHA. We have previously shown that heat-killed B. abortus (HKBA) can downregulate the PHA-induced increase of CD4+/CD25+ and CD14+/CD80+ cells of brucellosis patients. In the present study, we investigate the effect ofE. coliLPS, as a potent stimulant of monocytes and autologous T-lymphocytes, on the PHA-cultured PBMCs of the same groups of patients. Thirteen acute brucellosis (AB) patients, 22 chronic brucellosis (CB) patients, 11 “cured” subjects, and 15 healthy volunteers were studied. The percentage of CD4+/CD25+ and CD4+/CD28+ T-lymphocytes as well as CD14+/CD80+ monocytes were analyzed by flow cytometry after PBMCs culture with PHA plusE. coliLPS. A significant decrease in the percentage of CD4+/CD25+ and CD4+/CD28+ T-lymphocytes was observed in CB compared to AB. In HKBA cultures, compared toE. coliLPS-cultures, there was a significant reduction of CD4+/CD25+ T-lymphocytes in all groups and CD14+/CD80+ in patients groups. We suggest that Brucella can modulate host immune response, leading to T-cell anergy and chronic infection.


    • 1 October 2007
      • Vol. 11  (4) , 210-5

    Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center.

    by P Boura, K Tselios, P Skendros, S Kamali, A Sarantopoulos, M Raptopoulou-Gigi

    OBJECTIVE-METHODS: Adamantiades-Behcet disease (ABD) is a multi-systemic vasculitis of unknown origin, with a characteristic geographic distribution, that affects vessels of all kinds and sizes and is characterized by recurrent mucosal, skin and ocular lesions. In the present study, a series of 36 patients from Northern Greece is analyzed retrospectively in regard to the epidemiological, clinical and immunological parameters. All patients had recurrent oral ulcerations (36/36, 100%), while 23/36 (63.9%) experienced genital ulcerations and 22/36 (61.1%) developed ocular disease. Skin manifestations were observed in 23/36 patients (63.9%) and pathergy test was found positive in 14/36 patients (38.9%). Other manifestations included central nervous system involvement, recurrent genitourinary inflammations, arthralgias and superficial thrombophlebitis. Laboratory findings were not specific, partly reflecting the severity of inflammation. Ocular disease was more often observed in HLA-B51 (+) patients (20/31, 64.5%) than in HLA-B51 (-) patients. Standard of care (SOC) treatment consisted of cyclosporine A, azathioprine, methylprednisolone and aspirin, whereas refractory disease was treated with intravenous pulses of methylprednisolone and cyclophosphamide. Occasionally, anti-TNF agents (infliximab) were applied to treat refractory ocular disease. The findings of the present study come in agreement with those reported for other Mediterranean series. HLA-B51 seems to predispose to more severe disease, while early therapeutic intervention is beneficial for these patients.

  • Concurrent relapsing central nervous system and ocular involvement in a case of life-threatening Adamantiades-Behçet Disease (ABD)

    by P. Boura, K. Tselios, S. Kamali, P. Skendros, A. Sarantopoulos, F. Topouzis

    Adamantiades-Behçet disease (ABD) is characterised by oral and genital ulcerations, skin lesions and ocular manifestations and, rarely, by central nervous system (CNS) involvement. Neuro-Behçet disease (NBD) is categorised to parenchymal or non-parenchymal, while combined CNS disease is rarely reported in the literature. A case of NBD, with severe relapsing ocular and neurological disease of combined pattern is presented. Neurological complications included brainstem manifestations, as well as neurovascular involvement, while ocular involvement consisted of bilateral uveitis and branch retinal vein occlusion. Manifestations responded to corticosteroid plus cyclophosphamide pulse therapy. Maintenance therapy included cyclosporine A, azathioprine and corticosteroids. Case individualities are discussed, focusing on scepticism concerning treatment of NBD relapses in the long term.


  • Open Access

    CD80/CD28 co-stimulation in human brucellosis

    by P. Skendros, P. Boura, F. Kamaria, M. Raptopoulou-Gigi

    Despite treatment, 10–30% of brucellosis patients develop chronic disease, characterized by atypical clinical picture and/or relapses. A defective T helper 1 (Th1) response and a long percentage of CD4+/CD25+ cells have been described in chronic brucellosis patients. CD80/CD28 co-stimulation is critical for an efficient Th1 response and has not been studied previously in human brucellosis. In order to investigate the role of CD80/CD28 co-stimulation, 13 acute brucellosis patients (AB), 22 chronic brucellosis patients (CB, 12/22 relapsing type-CB1 and 10/22 atypical type-CB2), 11 ‘cured’ subjects and 15 healthy volunteers (controls) were studied. The percentage of CD4+/CD28+ T lymphocytes and CD14+/CD80+ monocytes were analysed by flow cytometry both ex vivo and after phytohaemagglutinin (PHA)-stimulation with or without heat-killed Brucella abortus (HkBA). Ex vivo analysis showed no differences between all groups studied. PHA stimulation up-regulated the percentage of CD80+ monocytes in AB compared to ‘cured’ subjects and controls (P < 0·001), although the proportion of CD4+/CD28+ cells did not alter. A higher percentage of CD80+ monocytes was observed in the CB1 subgroup, compared to AB, ‘cured’ subjects and controls (P = 0·042, < 0·001 and < 0·001, respectively). CB2 was characterized by a lower percentage of CD80+ monocytes in comparison to CB1 (P = 0·020). HkBA in PHA cultures down-regulated the percentage of CD80+ monocytes compared to PHA alone in all groups, especially in AB and CB patients (P < 0·001 and P = 0·007, respectively). In conclusion, the diminished percentage of CD4+/CD25+ T cells in CB is not associated with inadequate CD80/CD28 co-stimulation. We speculate that differential frequency of CD80+ monocytes after PHA stimulation could serve as a qualitative parameter of disease status, related to the different clinical forms of chronic brucellosis.


  • Eosinophilic cellulitis (Wells' syndrome) as a cutaneous reaction to the administration of adalimumab

    by P Boura, A Sarantopoulos, I Lefaki, P Skendros, P Papadopoulos

    Three to 4 hours after the second adalimumab injection (15 days later), the patient presented at the emergency department with chest discomfort, epigastralgia, fever (38.4°C), rigor, fatigue, and malaise. At the same time, at the injection site (left thigh), a violaceous plaque (10×9 cm) had developed, emerging as an erythematous urticarial oedema (fig 1A⇓). Laboratory …


  • Intracerebral hemorrhage in a patient with SLE and catastrophic antiphospholipid syndrome (CAPS): report of a case

    by Panagiota Boura, Savas Papadopoulos, Konstantinos Tselios, Panagiotis Skendros, Olga Dioritou, Georgios Malamis, Pantelis Makris, Nikolaos Lefkos

    A 31-year-old woman was admitted to the hospital for investigation of left lower limb thrombophlebitis. History, physical examination, and laboratory investigations led to the diagnosis of systemic lupus erythematosus (SLE), complicated by secondary antiphospholipid syndrome (APS). Treatment included steroids, azathioprine, aspirin, and low molecular weight heparin. Sixty-three days later, she was admitted to the hospital again because of high fever, macroscopic hematuria, and dyspnea. Laboratory testing showed anemia and impaired renal function. High-resolution chest computed tomography (CT) revealed bilateral multiple peribronchial infiltrates with hemorrhage. Magnetic resonance imaging (MRI) angiography of the kidneys revealed left renal vein thrombosis combined with ischemia of the left kidney. Cyclophosphamide and methylprednisolone pulse treatment as well as intravenous immunoglobulins were started immediately. Despite intensive immunosuppressive and supportive treatment, she suffered three relapses of alveolar hemorrhage and died on day 40, due to severe intracerebral bleeding. The final diagnosis was catastrophic APS with diffuse alveolar hemorrhage and kidney involvement. The unusual combination of recurrent alveolar hemorrhage and death from intracerebral hemorrhage rather than thrombosis in a CAPS patient is discussed.